{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,15]],"date-time":"2026-08-15T10:53:41Z","timestamp":1786791221658,"version":"build-2736575974"},"reference-count":30,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2019,5,21]],"date-time":"2019-05-21T00:00:00Z","timestamp":1558396800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2019,5,21]],"date-time":"2019-05-21T00:00:00Z","timestamp":1558396800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100002336","name":"Daiichi Sankyo Company","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100002336","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Hum Hypertens"],"published-print":{"date-parts":[[2019,7]]},"DOI":"10.1038\/s41371-019-0207-x","type":"journal-article","created":{"date-parts":[[2019,5,21]],"date-time":"2019-05-21T16:29:01Z","timestamp":1558456141000},"page":"542-551","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":62,"title":["Efficacy and safety of esaxerenone (CS-3150) for the treatment of essential hypertension: a phase 2 randomized, placebo-controlled, double-blind study"],"prefix":"10.1038","volume":"33","author":[{"given":"Sadayoshi","family":"Ito","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroshi","family":"Itoh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6508-4338","authenticated-orcid":false,"given":"Hiromi","family":"Rakugi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasuyuki","family":"Okuda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Satoru","family":"Yamakawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,5,21]]},"reference":[{"key":"207_CR1","doi-asserted-by":"publisher","first-page":"765","DOI":"10.1016\/0140-6736(90)90878-9","volume":"335","author":"S MacMahon","year":"1990","unstructured":"MacMahon S, Peto R, Cutler J, Collins R, Sorlie P, Neaton J, et al. Blood pressure, stroke, and coronary heart disease. Part 1, Prolonged differences in blood pressure: prospective observational studies corrected for the regression dilution bias. Lancet. 1990;335:765\u201374.","journal-title":"Lancet"},{"key":"207_CR2","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1016\/S0140-6736(94)91285-8","volume":"344","author":"PK Whelton","year":"1994","unstructured":"Whelton PK. Epidemiology of hypertension. Lancet. 1994;344:101\u20136.","journal-title":"Lancet"},{"key":"207_CR3","first-page":"866","volume":"107","author":"RE Schmieder","year":"2010","unstructured":"Schmieder RE. End organ damage in hypertension. Dtsch Arztebl Int. 2010;107:866\u201373.","journal-title":"Dtsch Arztebl Int"},{"key":"207_CR4","first-page":"CD003653","volume":"1","author":"MI Perez","year":"2008","unstructured":"Perez MI, Musini VM. Pharmacological interventions for hypertensive emergencies. Cochrane Database Syst Rev. 2008;1:CD003653.","journal-title":"Cochrane Database Syst Rev"},{"key":"207_CR5","doi-asserted-by":"publisher","first-page":"1206","DOI":"10.1161\/01.HYP.0000107251.49515.c2","volume":"42","author":"AV Chobanian","year":"2003","unstructured":"Chobanian AV, Bakris GL, Black HR, Cushman WC, Green LA, Izzo JL Jr., et al. Seventh report of the Joint National Committee on prevention, detection, evaluation, and treatment of high blood pressure. Hypertension. 2003;42:1206\u201352.","journal-title":"Hypertension"},{"key":"207_CR6","doi-asserted-by":"publisher","first-page":"634","DOI":"10.1111\/j.1524-6175.2006.05504.x","volume":"8","author":"MA Tedesco","year":"2006","unstructured":"Tedesco MA, Natale F, Calabr\u00f2 R. Effects of monotherapy and combination therapy on blood pressure control and target organ damage: a randomized prospective intervention study in a large population of hypertensive patients. J Clin Hypertens (Greenwich). 2006;8:634\u201341.","journal-title":"J Clin Hypertens (Greenwich)"},{"key":"207_CR7","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1111\/j.1524-6175.2002.02045.x","volume":"4","author":"WC Cushman","year":"2002","unstructured":"Cushman WC, Ford CE, Cutler JA, Margolis KL, Davis BR, Grimm RH, et al. Success and predictors of blood pressure control in diverse North American settings: the antihypertensive and lipid-lowering treatment to prevent heart attack trial (ALLHAT). J Clin Hypertens (Greenwich). 2002;4:393\u2013404.","journal-title":"J Clin Hypertens (Greenwich)"},{"key":"207_CR8","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1038\/hr.2013.80","volume":"37","author":"K Shimamoto","year":"2014","unstructured":"Shimamoto K, Ando K, Fujita T, Hasebe N, Higaki J, Horiuchi M, et al. The Japanese Society of Hypertension Guidelines for the Management of Hypertension (JSH 2014). Hypertens Res. 2014;37:253\u2013390.","journal-title":"Hypertens Res"},{"key":"207_CR9","first-page":"1","volume":"9","author":"D Marver","year":"1983","unstructured":"Marver D, Kokko JP. Renal target sites and the mechanism of action of aldosterone. Min Electrolyte Metab. 1983;9:1\u201318.","journal-title":"Min Electrolyte Metab"},{"key":"207_CR10","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1056\/NEJMoa033263","volume":"351","author":"RS Vasan","year":"2004","unstructured":"Vasan RS, Evans JC, Larson MG, Wilson PW, Meigs JB, Rifai N, et al. Serum aldosterone and the incidence of hypertension in nonhypertensive persons. N Engl J Med. 2004;351:33\u201341.","journal-title":"N Engl J Med"},{"key":"207_CR11","doi-asserted-by":"publisher","first-page":"296","DOI":"10.1111\/j.1440-1681.1993.tb01687.x","volume":"20","author":"RD Gordon","year":"1993","unstructured":"Gordon RD, Ziesak MD, Tunny TJ, Stowasser M, Klemm SA. Evidence that primary aldosteronism may not be uncommon: 12% incidence among antihypertensive drug trial volunteers. Clin Exp Pharm Physiol. 1993;20:296\u20138.","journal-title":"Clin Exp Pharm Physiol"},{"key":"207_CR12","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1111\/j.1440-1681.1994.tb02519.x","volume":"21","author":"RD Gordon","year":"1994","unstructured":"Gordon RD, Stowasser M, Tunny TJ, Klemm SA, Rutherford JC. High incidence of primary aldosteronism in 199 patients referred with hypertension. Clin Exp Pharm Physiol. 1994;21:315\u20138.","journal-title":"Clin Exp Pharm Physiol"},{"key":"207_CR13","doi-asserted-by":"publisher","first-page":"1699","DOI":"10.2337\/dc07-0031","volume":"30","author":"GE Umpierrez","year":"2007","unstructured":"Umpierrez GE, Cantey P, Smiley D, Palacio A, Temponi D, Luster K, et al. Primary aldosteronism in diabetic subjects with resistant hypertension. Diabetes Care. 2007;30:1699\u2013703.","journal-title":"Diabetes Care"},{"key":"207_CR14","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1016\/S0952-3278(99)80020-9","volume":"60","author":"TL Goodfriend","year":"1999","unstructured":"Goodfriend TL, Egan BM, Kelley DE. Plasma aldosterone, plasma lipoproteins, obesity and insulin resistance in humans. Prostaglandins Leukot Ess Fat Acids. 1999;60:401\u20135.","journal-title":"Prostaglandins Leukot Ess Fat Acids"},{"key":"207_CR15","doi-asserted-by":"publisher","first-page":"514","DOI":"10.1038\/ajh.2011.245","volume":"25","author":"H Shibata","year":"2012","unstructured":"Shibata H, Itoh H. Mineralocorticoid receptor-associated hypertension and its organ damage: clinical relevance for resistant hypertension. Am J Hypertens. 2012;25:514\u201323.","journal-title":"Am J Hypertens"},{"key":"207_CR16","doi-asserted-by":"publisher","first-page":"661","DOI":"10.1016\/j.amjmed.2016.01.039","volume":"129","author":"M Epstein","year":"2016","unstructured":"Epstein M, Duprez DA. Resistant hypertension and the pivotal role for mineralocorticoid receptor antagonists: a clinical update 2016. Am J Med. 2016;129:661\u20136.","journal-title":"Am J Med"},{"key":"207_CR17","doi-asserted-by":"publisher","first-page":"534","DOI":"10.1038\/jhh.2015.119","volume":"30","author":"S Takahashi","year":"2016","unstructured":"Takahashi S, Katada J, Daida H, Kitamura F, Yokoyama K. Effects of mineralocorticoid receptor antagonists in patients with hypertension and diabetes mellitus: a systematic review and meta-analysis. J Hum Hypertens. 2016;30:534\u201342.","journal-title":"J Hum Hypertens"},{"key":"207_CR18","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1007\/s11906-016-0643-8","volume":"18","author":"H Narayan","year":"2016","unstructured":"Narayan H, Webb DJ. New evidence supporting the use of mineralocorticoid receptor blockers in drug-resistant hypertension. Curr Hypertens Rep. 2016;18:34.","journal-title":"Curr Hypertens Rep"},{"key":"207_CR19","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1016\/j.semnephrol.2014.04.006","volume":"34","author":"JS Hirsch","year":"2014","unstructured":"Hirsch JS, Drexler Y, Bomback AS. Aldosterone blockade in chronic kidney disease. Semin Nephrol. 2014;34:307\u201322.","journal-title":"Semin Nephrol"},{"key":"207_CR20","doi-asserted-by":"publisher","first-page":"352","DOI":"10.1001\/jamacardio.2018.0005","volume":"3","author":"PK Whelton","year":"2018","unstructured":"Whelton PK, Carey RM. The 2017 American College of Cardiology\/American Heart Association clinical practice guideline for high blood pressure in adults. JAMA Cardiol. 2018;3:352\u20133.","journal-title":"JAMA Cardiol"},{"key":"207_CR21","doi-asserted-by":"publisher","first-page":"3021","DOI":"10.1093\/eurheartj\/ehy339","volume":"39","author":"B Williams","year":"2018","unstructured":"Williams B, Mancia G, Spiering W, Rosei EA, Azizi M, Burnier M, et al. 2018 ESC\/ESH Guidelines for the management of arterial hypertension. Eur Heart J. 2018;39:3021\u2013104.","journal-title":"Eur Heart J"},{"key":"207_CR22","doi-asserted-by":"publisher","first-page":"709","DOI":"10.1016\/S0895-7061(02)02957-6","volume":"15","author":"MH Weinberger","year":"2002","unstructured":"Weinberger MH, Roniker B, Kraus SL, Weiss RJ. Eplerenone, a selective aldosterone blocker, in mild-to-moderate hypertension. Am J Hypertens. 2002;15:709\u201316.","journal-title":"Am J Hypertens"},{"key":"207_CR23","unstructured":"Selera tablets 25 mg\/Selera tablets 50 mg\/Selera tablets 100 mg [package insert 2007]. Tokyo: Pfizer Japan Inc. [in Japanese]."},{"key":"207_CR24","doi-asserted-by":"publisher","first-page":"266","DOI":"10.1016\/j.ejphar.2015.11.028","volume":"769","author":"K Arai","year":"2015","unstructured":"Arai K, Tsuruoka H, Homma T. CS-3150, a novel non-steroidal mineralocorticoid receptor antagonist, prevents hypertension and cardiorenal injury in Dahl salt-sensitive hypertensive rats. Eur J Pharm. 2015;769:266\u201373.","journal-title":"Eur J Pharm"},{"key":"207_CR25","doi-asserted-by":"publisher","first-page":"548","DOI":"10.1124\/jpet.116.234765","volume":"358","author":"K Arai","year":"2016","unstructured":"Arai K, Morikawa Y, Ubukata N, Tsuruoka H, Homma T. CS-3150, a novel nonsteroidal mineralocorticoid receptor antagonist, shows preventive and therapeutic effects on renal injury in deoxycorticosterone acetate\/salt-induced hypertensive rats. J Pharm Exp Ther. 2016;358:548\u201357.","journal-title":"J Pharm Exp Ther"},{"key":"207_CR26","doi-asserted-by":"publisher","first-page":"1821","DOI":"10.1111\/bcp.13616","volume":"84","author":"M Kato","year":"2018","unstructured":"Kato M, Furuie H, Shimizu T, Miyazaki A, Kobayashi F, Ishizuka H. Single- and multiple-dose escalation study to assess pharmacokinetics, pharmacodynamics and safety of oral esaxerenone in healthy Japanese subjects. Br J Clin Pharm. 2018;84:1821\u20139.","journal-title":"Br J Clin Pharm"},{"key":"207_CR27","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1161\/01.HYP.0000025146.19104.FE","volume":"40","author":"H Krum","year":"2002","unstructured":"Krum H, Nolly H, Workman D, He W, Roniker B, Krause S, et al. Efficacy of eplerenone added to renin-angiotensin blockade in hypertensive patients. Hypertension. 2002;40:117\u201323.","journal-title":"Hypertension"},{"issue":"11 Pt 1","key":"207_CR28","doi-asserted-by":"publisher","first-page":"925","DOI":"10.1016\/S0895-7061(03)01032-X","volume":"16","author":"MK Nishizaka","year":"2003","unstructured":"Nishizaka MK, Zaman MA, Calhoun DA. Efficacy of low-dose spironolactone in subjects with resistant hypertension. Am J Hypertens. 2003;16(11 Pt 1):925\u201330.","journal-title":"Am J Hypertens"},{"key":"207_CR29","doi-asserted-by":"publisher","first-page":"1021","DOI":"10.1161\/01.HYP.0000067463.13172.EA","volume":"41","author":"WB White","year":"2003","unstructured":"White WB, Duprez D, St Hillaire R, Krause S, Roniker B, Kuse-Hamilton J, et al. Effects of the selective aldosterone blocker eplerenone versus the calcium antagonist amlodipine in systolic hypertension. Hypertension. 2003;41:1021\u20136.","journal-title":"Hypertension"},{"key":"207_CR30","doi-asserted-by":"publisher","first-page":"990","DOI":"10.1016\/j.amjcard.2004.01.007","volume":"93","author":"GH Williams","year":"2004","unstructured":"Williams GH, Burgess E, Kolloch RE, Ruilope LM, Niegowska J, Kipnes MS, et al. Efficacy of eplerenone versus enalapril as monotherapy in systemic hypertension. Am J Cardiol. 2004;93:990\u20136.","journal-title":"Am J Cardiol"}],"container-title":["Journal of Human Hypertension"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.nature.com\/articles\/s41371-019-0207-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/s41371-019-0207-x","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/s41371-019-0207-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,20]],"date-time":"2023-05-20T21:23:56Z","timestamp":1684617836000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41371-019-0207-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,5,21]]},"references-count":30,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2019,7]]}},"alternative-id":["207"],"URL":"https:\/\/doi.org\/10.1038\/s41371-019-0207-x","relation":{},"ISSN":["0950-9240","1476-5527"],"issn-type":[{"value":"0950-9240","type":"print"},{"value":"1476-5527","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,5,21]]},"assertion":[{"value":"18 December 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 March 2019","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 April 2019","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 May 2019","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"SI, HI, and HR have received lecture fees and research funding from Daiichi Sankyo Co., Ltd. YO and SY are employees of Daiichi Sankyo Co., Ltd.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}